Carboplatin , a drug deried from cisplatin , is approed by fda Fda批准顺铂的衍生物-卡铂
2.
Carboplatin , a drug derived from cisplatin , is approved by fda Fda批准顺铂的衍生物-卡铂
3.
Treatment of malignant thoracic hydrops by carboplatin combined with new type interleukin 2治疗恶性胸腔积液
4.
The trial compared the effectiveness of avastin plus carboplatin and paclitaxel with chemotherapy by carboplatin and paclitaxel alone 试验中用阿瓦斯丁联合卡铂和紫杉醇化疗和单用卡铂和紫杉醇化疗效果进行对比。
5.
Carboplatin is one of the most important anticancer drugs among the second generation of platinum metal - based drugs , and widely used in clinics 摘要卡铂是第二代铂类金属抗癌药物最重要的药物之一，广泛应用于临床。
6.
The median overall survival time for patients in the avastin plus carboplatin and paclitaxel arm was 12 . 3 months versus 10 . 3 months for patients receiving only carboplatin and paclitaxel 阿瓦斯丁联合卡铂和紫杉醇的平均生存时间为12 . 3个月，与之相对的单用卡铂和紫杉醇的为10 . 3个月。
7.
They also differ from combined paclitaxel and carboplatin , where grade 4 alopecia and flushes are uniersally seen and peripheral neurotoxicity , particularly sensory neuropathy , in roughly one third of subjects 4级不良反应脱发和面部潮红一般普遍多见，外周神经毒性，特别是感觉神经病变发生率大致为三分之一，这些也与联合使用紫杉醇和卡铂不同。
8.
Conclusions the addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non ? small - cell lung cancer has a significant survival benefit with the risk of increased treatment - related deaths . ( clinicaltrials . gov number , nct00021060 [ clinicaltrials . gov ] 结论：紫杉醇-卡铂加上贝伐单抗治疗非小细胞肺癌，可明显延长生存期，但治疗相关性死亡风险也同时升高。
9.
In this thesis , the deposition properties and the release behavior after deposition of a low molecular model drug ( rhodamine b ) and four kinds of anti - cancer drugs ( daunorubicin ( dnr ) , adroamycin ( adm ) , cisplatin and carboplatin ) have been examined 本文还研究了小分子模型药物(罗丹明b ， rdb )和四种抗癌药物(顺铂， cisplatin ；卡铂， carboplatin ；柔红霉素， dnr ；阿霉素， adm )在聚电解质微胶囊中的自发沉积和释放性能。
10.
Gemcitabine plus carboplatin was associated with " moderate aderse reactions . " who grade 3 anemia , neutropenia and thrombocytopenia was seen in 7 . 6 % , 9 . 5 % , and 0 % , respectiely , on day 8 , and 15 . 5 % , 12 . 2 % , and 15 . 5 % , respectiely , on day 15 二氟脱氧胞嘧啶核苷联合卡铂给药伴随有“适度的副作用。 ”世界卫生组织划分的3级不良反应，贫血，嗜中性白血球减少和血小板减少的发生率，在第8天分别是7 . 6 ， 9 . 5和0 ，在第15天分别是15 . 5 ， 12 . 2和15 . 5 。
